Tenaya Therapeutics Past Earnings Performance
Past criteria checks 0/6
Tenaya Therapeutics's earnings have been declining at an average annual rate of -36.7%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-36.7%
Earnings growth rate
87.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -89.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation
Dec 20
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?
Aug 08Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely
Mar 07Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?
Dec 06Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment
Sep 06Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07
Aug 10Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?
Aug 08We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely
Mar 03Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth
Nov 01Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms
Aug 06Revenue & Expenses BreakdownBeta
How Tenaya Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -124 | 33 | 98 |
| 30 Sep 23 | 0 | -128 | 33 | 101 |
| 30 Jun 23 | 0 | -129 | 33 | 102 |
| 31 Mar 23 | 0 | -124 | 32 | 96 |
| 31 Dec 22 | 0 | -124 | 31 | 95 |
| 30 Sep 22 | 0 | -116 | 27 | 90 |
| 30 Jun 22 | 0 | -104 | 25 | 79 |
| 31 Mar 22 | 0 | -91 | 22 | 69 |
| 31 Dec 21 | 0 | -73 | 18 | 54 |
| 30 Sep 21 | 0 | -57 | 15 | 42 |
| 30 Jun 21 | 0 | -49 | 12 | 37 |
| 31 Mar 21 | 0 | -42 | 9 | 33 |
| 31 Dec 20 | 0 | -38 | 8 | 31 |
Quality Earnings: TNYA is currently unprofitable.
Growing Profit Margin: TNYA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TNYA is unprofitable, and losses have increased over the past 5 years at a rate of 36.7% per year.
Accelerating Growth: Unable to compare TNYA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TNYA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: TNYA has a negative Return on Equity (-89%), as it is currently unprofitable.